Human tumor organoids have advanced cancer modeling by preserving patient-specific heterogeneity and functional drug responses. However, translating organoid findings into routine decision-making remains challenging due to variability in culture conditions and incomplete reconstruction of the tumor microenvironment. In this review, we present a clear and actionable framework that positions tumor organoids as dynamic living biosensors, linking mechanistic studies, tumor microenvironment reconstruction, functional drug-response phenotyping, and precision-therapy decision-making.
The review summarizes major sources and establishment strategies, and highlights how culture engineering and biomaterials shape phenotype stability and drug-response interpretability. We further integrate tumor organoid microenvironment co-culture designs and emerging enabling technologies that improve scalability and standardization for translational use.
Key findings from this review include:
Overall, this review provides an integrated perspective on how tumor organoids can be engineered and applied for cancer modeling and precision therapy. These insights support improved clinical correlation and more reliable functional testing. Future work should prioritize quality control, cross-laboratory standardization, and ethical governance to enable broader real-world implementation.
Protein & Cell
Experimental study
Not applicable
Harnessing human tumor organoids for cancer modeling and precision therapy
16-Feb-2026